Muscle mass loss and wasting are characteristic features of patients with chronic conditions including cancer. Beta-adrenoceptors attenuate muscle wasting. We hypothesized that specific muscle atrophy signaling pathways and altered metabolism may be attenuated in cancer cachectic animals receiving treatment with the beta 2 agonist formoterol. In diaphragm and gastrocnemius of tumor-bearing rats (intraperitoneal inoculum, 10 8 AH-130 Yoshida ascites hepatoma cells, 7-day study period) with and without treatment with formoterol (0.3 mg/kg body weight/day/7days, subcutaneous), atrophy signaling pathways (NF-κB, MAPK, FoxO), proteolytic markers (ligases, proteasome, ubiquitination), autophagy markers (p62, beclin-1, LC3), myostatin, apoptosis, muscle metabolism markers, and muscle structure features were analyzed (immunoblotting, immunohistochemistry). In diaphragm and gastrocnemius of cancer cachectic rats, fiber sizes were reduced, levels of structural alterations, atrophy signaling pathways, proteasome content, protein ubiquitination, autophagy, and myostatin were increased, while those of regenerative and metabolic markers (myoD, mTOR, AKT, and PGC-1alpha) were decreased. Formoterol treatment attenuated such alterations in both muscles. Muscle wasting in this rat model of cancer-induced cachexia was characterized by induction of significant structural alterations, atrophy signaling pathways, proteasome activity, apoptotic and autophagy markers, and myostatin, along with a significant decline in the expression of muscle regenerative and metabolic markers. Treatment of the cachectic rats with formoterol partly attenuated the structural alterations and atrophy signaling, while improving other molecular perturbations similarly in both respiratory and limb muscles. The results reported in this study have relevant therapeutic implications as they showed beneficial effects of the beta 2 agonist formoterol in the cachectic muscles through several key biological pathways. Word count: 250 ABSTRACT 24
Muscle mass loss and dysfunction are common systemic manifestations in patients with 80 chronic conditions such as chronic obstructive pulmonary disease (COPD), heart and renal 81 failure, diabetes, and cancer [1] [2] [3] [21] [22] [23] 61, 62] . In patients with critical illness, severe muscle 82 wasting also takes place very rapidly, impairing the patients' outcome [21] . Importantly, 83 muscle wasting and atrophy of the lower limb muscles entails a reduction of the patients' 84 quality of life and has been shown to predict morbidity and mortality regardless of the 85 underlying condition [3, 22, 23, 34, 37, 42, 52, 55] . 86 Biological mechanisms such as increased oxidative stress, epigenetic regulation, 87 metabolic derangements, sarcomere disruptions, contractile protein loss, autophagy, enhanced 88 proteolysis, and specific signaling pathways have been demonstrated to be involved in the 89 pathophysiology of muscle wasting associated with chronic diseases including cancer [2,4-90 6,8,14-17, [24] [25] [26] [27] 35, 36, [43] [44] [45] [46] . Mitogen-activated protein kinases (MAPK) and nuclear factor 91 (NF)-κB are central regulators of a great variety of cellular processes including adaptive and 92 maladaptive responses to cellular stress in skeletal muscles [32] . Activation of MAPK, NF-93 κB, and forkhead box O (FoxO) transcription factors was shown to mediate muscle wasting in 94 an experimental model of cancer-induced cachexia [13, 15, 40] . Indeed, treatment of the 95 cachectic mice with either NF-κB or MAPK inhibitors significantly improved muscle mass 96 loss as a result of an attenuation of muscle proteolysis [15] . 97
The ubiquitin-proteasome system has been shown to degrade muscle proteins in 98 experimental models of cancer-induced cachexia [15, 54, 59, 60] and disuse muscle atrophy 99 [16] . Interestingly, the proteasome inhibitor bortezomib was shown to restore diaphragm 100 muscle contractile function and myosin heavy chain content (MyHC) following coronary 101 heart failure [59] and elastase-induced emphysema [60] in mice. In a model of cancer-induced 102 cachexia, however, bortezomib did not significantly attenuate muscle mass or function loss In skeletal muscles, other cellular pathways can also be targeted for the treatment of 105 cachexia. For instance, canonical beta-agonist signaling improves muscle metabolism through 106 the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), 107 that activates protein kinase A [49] . In skeletal muscles, the proportions of beta 2 receptors are 108 significantly more abundant than those of beta 1 -and beta 3 -adrenoceptors [63]. Part of the 109 beneficial effects induced by beta-agonist signaling involves a decrease in protein 110 degradation, an increase in protein anabolism or both [49] . Interestingly, skeletal muscle 111 growth can be achieved following treatment with beta-adrenoceptor agonists when 112 administered at higher doses than those normally used for the treatment of airways diseases 113 such as COPD [49] . In this regard, the long-acting beta 2 agonist formoterol, which has a rapid 114 onset of action, while maintaining a long duration of action, has been shown to induce 115 significant beneficial effects on skeletal muscles through several biological mechanisms [10-116 12,57]. Whether atrophy signaling may be attenuated by treatment with formoterol as another 117 beneficial effect of beta 2 -adrenoceptor therapy in muscles deserves further attention in models 118 of cachexia. 119
On this basis, we hypothesized that signaling pathways that lead to muscle mass loss 120 and altered metabolism may be attenuated in cancer cachectic animals receiving treatment 121 with the beta 2 agonist formoterol. In the current investigation, experiments on the diaphragm 122 muscle have also been conducted as the main respiratory muscle. This approach enabled us to 123 elucidate whether the profile of the target biological events may be influenced by the activity 124 of the muscles. Accordingly, the study objectives were defined as follows: 1) to analyze 125 levels of expression of signaling pathways such as NF-κB, MAPK, and FoxO and proteolytic 126 markers, 2) to determine expression levels of autophagy markers, 3) to assess levels of 127 transcription factors involved in muscle mass maintenance and metabolism, and 4) to 128 investigate structural features in both diaphragm and gastrocnemius muscles of cachectic rats 129 M A N U S C R I P T 
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Food and water were administered to the rats for the entire duration of the study. All the 154 animals were maintained at a temperature of 22 ± 2 °C with a regular light-dark cycle (lights 155 were on from 08:00 a.m. to 08:00 p.m.) and had free access to food and water. Body weight 156 was determined in all animals on day 0 and immediately prior to their sacrifice on day 7. 157
Tumor weights were determined in all animals upon sacrifice. The percentage of body weight 158 gain at the end of the study period was calculated as follows: [(body weight on day 7 -tumor 159 weight on day 7) -body weight on day 0]/ body weight on day 0 x 100. 160
Sacrifice and sample collection 161
On day 7 after tumor transplantation, the rats were weighed and anesthetized with an 162 intraperitoneal injection of 3:1 ketamine/xylazine mixture (Imalgene 1000, Rhone Merieux, 163
France and Rompun®, Bayer AG, Leverkusen, Germany, respectively). In all animals, the 164 pedal and blink reflexes were evaluated in order to verify total anesthesia depth. Each tumor 165 was harvested from the peritoneal cavity, and the volume and cellularity were evaluated. The 166 diaphragm and gastrocnemius muscles were obtained from all the rats. In all samples, a 167 fragment of the muscle specimens was immediately frozen in liquid nitrogen and 168 subsequently stored at -80ºC, while the remaining specimen was immersed in an alcohol-169 formol bath to be thereafter embedded in paraffin until further use. Frozen tissues were used 170 to assess the expression of the target molecular markers, whereas paraffin-embedded tissues 171 were used for the histological studies. 172
Muscle biology analyses 173
All the muscle biological experiments were performed in the same laboratory at Hospital del 174
Mar-IMIM-Universitat Pompeu Fabra (Barcelona). 
Statistical Analysis 256
The normality of the study variables was verified using the Shapiro-Wilk test. Equality of 257 variance for the study variables was tested using the Levene's test. As established results are 258 represented as mean (standard deviation) [41] . Comparisons between all study groups were 259 analyzed using the two-way analysis of variance (ANOVA). Subsequently, Tukey post-hoc 260 analysis was used to adjust for multiple comparisons among the different study groups. The 261 sample size chosen was based on previous studies [14-18,45,46,50] and on assumptions of 262 80% power to detect an improvement of more than 20% in measured outcomes at a level of 263 significance of p≤ 0.05. All statistical analyses were performed using the Statistical Package 264 for the Social Science (Portable SPSS, PASW statistics 18.0 version for Windows, SPSS Inc., 265
Chicago, IL, USA). 266 267 3. RESULTS 268
Physiological characteristics of the study animals 269
At the end of the study period, cancer-cachexia rats exhibited a significant reduction in final 270 body weight and body weight gain parameters compared to non-cachexia controls ( Table 1) . 271
Treatment with formoterol induced a significant improvement in body weight gain of cancer-272 cachectic rats ( Table 1 ). The weights of diaphragm and gastrocnemius muscles were 273 significantly reduced in cancer-cachexia rats compared to non-cachexia controls ( Table 1) . 274
Treatment with formoterol elicited a significant improvement in the weight of the 275 gastrocnemius (similar to that in non-tumor controls), while it did not significantly ameliorate 276 the weight of the diaphragm in the cancer-cachectic rats ( Table 1) . No significant differences 277 were observed in the tumor cell content or weight between cancer-cachexia rats with or 278 without treatment with formoterol (Table 1) . 279
Effects of formoterol on muscle phenotype 282
The proportions of slow-and fast-twitch fibers did not significantly differ in the study 283 muscles between cancer-cachectic rats and non-cachexia control animals (Table 2 and Figure  284 S1). The fiber cross-sectional areas significantly decreased in both diaphragm and 285 gastrocnemius muscles of cancer-cachexia rats compared to non-cachexia controls ( Table 2  286 and Figure S1 ). Specifically, in the cachectic rats compared to non-cachectic control animals, 287 the sizes of slow-and fast-twitch fibers were reduced by 23% and 32%, respectively, in the 288 diaphragm and by 28% and 21%, respectively, in the gastrocnemius (Table 2 and Figure S1 ). 289
Treatment of the cachectic rats with formoterol induced a significant improvement of the sizes 290 of the slow-and fast-twitch fibers in the study muscles: 19% and 30% (diaphragm, 291 respectively) and 78% and 26% (gastrocnemius, respectively), compared to non-treated 292 control animals (Table 2 and Figure S1 ). Recovery of fiber sizes reached levels observed in 293 the non-cachectic control animals following treatment with formoterol only in the 294 gastrocnemius, particularly in the slow-twitch fibers (Table 2 and Figure S1 ). 295
Muscle structural abnormalities were significantly greater in both diaphragm and 296 gastrocnemius muscles of cancer-cachexia rats than in non-cachexia controls (Table 3 and 297 Figure S2 ). Treatment with formoterol significantly improved the structural abnormalities in 298 both muscles, especially in the diaphragm, of the cachectic rats, and levels were similar to 299 those found in the non-cachectic control animals (Table 3 and Figure S2 ). 300
Effects of formoterol on atrophy signaling pathways in muscles 301
Activated NF-kB p65 levels significantly increased in diaphragm and gastrocnemius muscles 302 of cancer-cachexia rats compared to non-cachexia controls, and formoterol treatment 303 attenuated such an increase in both muscles, whose levels were similar to those in the control 304 animals ( Figures 1A and S3-4) . Activated IkB-alpha levels were significantly lower in 305 respiratory and limb muscles of cancer-cachectic rats than in non-cachexia controls ( Figures 1C and S3-4) . Formoterol 308 treatment did not induce any significant effect on activated IkB-alpha or FoxO-3 protein 309 levels in the study muscles of the cancer-cachexia rats, and in the latter marker levels were 310 similar to the controls (Figures 1B, 1C , and S3-4). No significant differences were observed 311 in the levels of activated FoxO-1, ERK1/2, or p38 in any study muscle between cancer-312 cachexia rats and non-cachexia controls in any muscle among study groups ( Figures 1D-F and 313 S3-4). 314
Effects of formoterol on proteolytic markers in muscles 315
In diaphragm and gastrocnemius muscles, gene expression of MuRF-1 significantly increased 316 in both muscles of cancer-cachexia rats compared to non-cachexia controls, while no 317 significant differences were observed in MuRF-1 protein levels in any muscle among study 318 groups (Figures 2A and S5 ). Expression of atrogin-1 was only significantly increased in 319 gastrocnemius muscles of cancer-cachexia rats compared to non-cachexia controls, but again 320 no significant differences were observed in atrogin-1 protein levels in muscles among the 321 study groups (Figures 2B and S5 ). No significant differences were observed in either gene 322 expression or protein levels of TRIM32 in any muscles among study groups ( Figures 2C and  323   S5 ). Total protein ubiquitination and C8-20S subunit levels were significantly higher in both 324 muscles of cancer-cachexia rats than in non-cachexia animals ( Figures 2D-E and S5 ). 325
Treatment with formoterol induced a significant decrease in C8-20S protein levels of 326 diaphragm and gastrocnemius muscles in the cancer-cachectic rats, whose levels were similar 327 to those in the controls, while protein ubiquitination was not modified by the beta 2 agonist 328 ( Figures 2D and S5) . 329
Effects of formoterol on autophagy markers in muscles 330
Protein levels of P62 and beclin-1 significantly increased in the diaphragm of cancer-cachexia 331 rats compared to non-cachexia controls ( Figures 3A-B and S6) . A significant rise in LC3 332 protein levels was also detected in diaphragm and gastrocnemius muscles of cancer-cachexia 333 M A N U S C R I P T
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15 rats compared to non-cachexia controls, and treatment with formoterol of the former animals 334 significantly attenuated such an increase in both muscles (similar to control rats) ( Figures 3C  335 and S6). Myostatin protein levels significantly increased in both muscles of cancer-cachectic 336 rats compared to non-cachexia controls and formoterol treatment significantly attenuated such 337 an increase (similar to controls, Figures 3D and S6) . Levels of calpain-cleaved α II-spectrin in 338 diaphragm and gastrocnemius did not significantly differ between cancer-cachexia rats and 339 non-cachexia controls ( Figures 3E and S6) . 340
Effects of formoterol on apoptosis markers in muscles 341
TUNEL positively-stained nuclei were significantly higher in diaphragm and gastrocnemius 342 muscles of cancer-cachexia rats than in non-cachexia controls ( Figures 4A and S7 ). Treatment 343 of cancer-cachexia rats with formoterol significantly reduced TUNEL positively-stained 344 nuclei in the diaphragm (similar to controls), but not in the limb muscle ( Figures 4A and S7) . 345
In cancer cachectic rats, BAX protein levels were increased only in the diaphragm, and 346 formoterol treatment significantly reduced those levels in the respiratory muscle of the 347 cachectic animals ( Figures 4B and S8 ). Protein levels of BCL-2 did not differ among any of 348 the study muscles ( Figures 4C and S8) . 349
Effects of formoterol on markers of muscle mass maintenance and metabolism 350
In diaphragm and gastrocnemius muscles of cancer-cachexia rats, levels of mTOR were 351 significantly reduced compared to non-cachexia controls ( Figures 5A and S9) . In the current study, the hypothesis has been confirmed: administration of the beta 2 agonist 364 for seven days attenuated the activation of atrophy signaling pathways and myostatin system, 365 while improving the expression of proteolytic markers and muscle structural alterations in 366 both diaphragm and gastrocnemius muscles of the cancer cachectic rats. Levels of markers 367 involved in muscle repair and maintenance were not affected by formoterol treatment, 368 suggesting that the beta 2 agonist rather prevented proteolysis than favored muscle repair and 369 protein anabolism. Interestingly, formoterol treatment did not elicit any significant differences 370 in tumor weights or number of cells in the cancer cachectic rats. The most relevant findings 371 observed in the study are discussed below. 372
The Yoshida AH-130 ascites hepatoma is a suitable approach to study the underlying 373 
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The novelty in the present study was the attenuation or even the improvement in the 385 atrophy signaling pathways analyzed in the muscles of the cancer cachectic rats in response to 386 treatment with formoterol for seven days. Importantly, levels of the proteolytic markers total 387 protein ubiquitination and proteasome content were also significantly attenuated, especially 388 the latter, in both respiratory and limb muscles of the cancer cachectic rats treated with the 389 beta 2 agonist for one week. These findings suggest that formoterol attenuate ATP-dependent 390 proteolysis through inhibition of the ubiquitin-proteasome proteolytic pathway. In fact, a 391 previous study demonstrated a significant downregulation of the expression of proteasome 392 subunits in limb muscles of cancer cachectic rats treated with formoterol [10] . It should be 393 mentioned that in this model of cancer cachexia, muscle protein levels of MAPK signaling 394 pathway and those of the E3 ligases MuRF-1, atrogin-1, and TRIM32 did not significantly 395 differ between cachectic and non-cachectic conditions, and formoterol treatment did not have 396 any significant effect on those muscles. Nonetheless, gene expression levels of MuRF-1 were 397 upregulated in both diaphragm and gastrocnemius, while those of atrogin-1 were only 398 upregulated in the cachectic limb muscle. Moreover, gene and protein expression levels of 399 TRIM32 did not significantly differ among study groups for any of the muscles. Collectively, 400 these results imply a potential transcriptional regulation of the atrogenes in this model as 401 previously reported [9] . On the other hand, specific characteristics of experimental models, 402 type of tumors, or duration of the study period may account for differences encountered in the 403 levels of expression of the proteolytic markers in the target muscles across studies [15, 18] . 404
Indeed, a recent study from our group showed that the ubiquitin-proteasome system was not 405 involved in the process of muscle wasting associated with lung cancer carcinogenesis in mice 406 [50] . 407
As expected, body and muscle weights were significantly reduced in the cancer 408 cachectic rats and formoterol treatment attenuated such alterations. Interestingly, atrophy of 409 both slow-and fast-twitch fibers was also observed in the respiratory and limb muscles of the M A N U S C R I P T
18 cancer cachectic rats, as shown in other models [15, 18, 50] . Interestingly, formoterol therapy 411 for seven days significantly reversed (to control levels or even better in the limb muscle) the 412 atrophy of the muscle fibers, especially of the slow-twitch fibers in the gastrocnemius, in 413 which the improvement was substantial. Indeed, previous results have already demonstrated 414 that beta 2 agonists particularly improved the function and structure of the slow-twitch fibers 415 [38] . These observations also reinforce the validation of the model and the effects of treatment 416 with beta-adrenoceptors, as also previously demonstrated in other experimental conditions 417 [10] [11] [12] 38] . 418 A significant rise in several structural abnormalities such as inflammatory cell and 419 internal nuclei counts was also observed in the diaphragm and gastrocnemius muscles of the 420 cancer cachectic rats. Importantly, treatment with formoterol significantly attenuated all the 421 structural alterations, especially in the diaphragm, of the cachectic rats. These results also 422 suggest that a damage-repair mechanism may take place similarly in the fibers of both 423 respiratory and limb muscles during the muscle wasting process. As a matter of fact, the rise 424 in inflammatory cells and internal nuclei imply the existence of an underlying repair process 425 following injury of the cachectic muscles during the muscle wasting process. 426
Moreover, as previously shown in muscles of cachectic animals [7, 14] and in patients 427 with COPD [4,46] and LC [46] , the number of apoptotic nuclei was also significantly 428 increased in the respiratory and limb muscles of the tumor-bearing rats. A significant rise in 429 protein levels of BAX was only observed in the diaphragm muscle of the cancer cachectic 430 rats, and formoterol significantly attenuated such an increase in the respiratory muscle. It is 431 likely that differences in the activity of each type of muscle may account for the differences in 432 the levels of expression of the apoptotic marker BAX as the diaphragm must maintain 433 continuously its activity in the animals. Levels of the antiaopoptotic BCL-2 did not differ in 434 any muscle among the study groups of rats.
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A relevant finding in the study was the specificity of the effects of the beta 2 agonist 436 formoterol on skeletal muscles but not on tumor growth (cell numbers) or size of the cancer 437 cachectic rats. Interestingly, it has been suggested that beta-adrenergic signaling regulate 438 tumor growth among other cellular processes and that beta-blockers may be used as adjuvant 439 therapies in the management of patients with cancer [19, 20, 39] . In the study, formoterol 440 treatment did not induce any significant effects on tumor growth in the cancer cachectic rats, 441 implying that the beta 2 agonist exerted selective effects on the muscle fibers of the animals. 442
A novel finding in the study was the significant rise in the levels of the autophagy 443 markers p62, beclin-1, and LC3 in the limb muscle and diaphragm, especially the latter, of the 444 cancer cachectic rats compared to the non-cachectic control animals. These results are in 445 keeping with a previous study conducted on a mouse model of carcinogenesis induced by 446 urethane administration [50], in which autophagy markers were also increased in both 447 diaphragm and gastrocnemius of mice with lung cancer cachexia. Indeed, in that study [50] 448 autophagy and apoptosis were the most relevant contributors to muscle atrophy in both 449 respiratory and limb muscles. 450
In the current investigation, beclin-1 and p62 were significantly increased only in the 451 diaphragm of the cancer cachectic rats, while a rise in LC3-II/I ratio levels were seen in both 452 respiratory and limb muscles of these rodents. These observations suggest that autophagy is 453 differentially regulated in the diaphragm in this model of cancer cachexia probably to 454 maintaining the turnover of cell components as previously implied in the pathophysiology of 455 muscular dystrophies, in which autophagy was defective [29] . A novel finding in the 456 investigation was the significant reduction in LC3-II/I ratio levels induced by formoterol 457 therapy in both diaphragm and gastrocnemius muscles. These results were partly in agreement 458 with those previously reported in a model of fast-twitch muscle hypertrophy [30] , in which 459 the kinetics of anabolic and catabolic markers and autophagy were studied in response to 460 treatment with formoterol at several time-points. Importantly, formoterol therapy for several Interestingly, protein levels of myostatin were significantly greater in both respiratory 464 and limb muscles of cancer cachectic rats. These findings are similar to previous reports, in 465
which myostatin system was also upregulated in models of cancer-induced cachexia [11, 15] . 466 Furthermore, formoterol also induced a downregulation of the myostatin levels as a result of 467 an upregulation of follistatin expression, thus, improving muscle mass in the cachectic rats 468
[11]. The current observations are also in agreement with the previous findings [11] as to the 469 effects of treatment with the beta 2 agonist in the cachectic rats. 470
Levels of mTOR as a marker of protein synthesis were significantly decreased in the 471 diaphragm and gastrocnemius of the cancer cachectic rats. Importantly, in these muscles of 472 tumor-bearing rats treated with formoterol for seven days, mTOR levels did not differ from 473 those seen in the non-treated cachectic animals. Protein levels of activated AKT were also 474 reduced in the gastrocnemius, but not the respiratory muscle, of the cancer cachectic rats, and 475 formoterol did not elicit a significant improvement in its levels in any of the study muscles. 476
These findings are in contrast with previous results in which AKT-mTOR pathway was 477 activated in response to formoterol therapy in the limb muscles of rats, especially in the early 478 phases of the treatment [30] . Differences in experimental design and models may account for 479 the discrepancies among studies. 480
Alterations in the levels of muscle regeneration were previously reported in cancer-481 cachexia models [58] . Similarly, in the present study, protein levels of myoD were also 482 significantly lower in both respiratory and limb muscles of the cancer cachectic rats than in 483 the controls. Importantly, formoterol treatment prevented a further decline in myoD in the 484 cachectic muscles. PPARs are powerful regulators of skeletal muscle metabolism and 485 mitochondrial biogenesis [31, 33] . Moreover, they also play a role in the fiber type shift 486 towards a more resistant phenotype in skeletal muscles [47] . Signaling of muscle atrophy M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 21 may also be mediated by PPARs in cachectic conditions [48] . In the present study, levels of 488 PGC-1alpha, but not those of PPAR-alpha or PPAR-gamma, were significantly lower in 489 respiratory and limb muscles of the cachectic rats than control rodents. These findings are in 490 line with previous investigations, in which PPAR levels were altered in muscles of cachectic 491 rats [28] and mice [50, 53] and lower limb muscles of patients with respiratory cachexia [48] . 492
Treatment with the beta 2 agonist prevented a further decline in PGC-1alpha levels of both 493 study muscles of the cancer cachectic rats, as previously shown to occur in a rat model of 494 hypertrophy [30] . Collectively, these findings imply that important metabolic alterations took 495 place in both respiratory and limb muscles that were partly attenuated by treatment with the 496 beta 2 agonist formoterol in this experimental model of cancer-induced cachexia. 497
Conclusions 498
We conclude that muscle wasting in this in vivo model of cancer-induced cachexia is 499 characterized by the induction of significant structural alterations, atrophy signaling 500 pathways, proteasome activity, autophagy markers, and myostatin system, along with a 501 significant decline in the expression of muscle regenerative and metabolic markers of both 502 respiratory and limb muscles in a similar fashion. Treatment of the cachectic rats with 503 formoterol for seven days partly attenuated the structural alterations, while improving atrophy 504 signaling pathways and other molecular perturbations in both diaphragm and gastrocnemius. 505
The results reported in this study have relevant therapeutic implications as they showed 506 beneficial effects of the beta 2 agonist formoterol in respiratory and limb muscles of the 507 cachectic rats through several key biological pathways in a similar manner. Tumor cell content --3.6×10 9 (4·10 8 ) 3.4×10 9 (6·10 8 ) 
